PTGS2 and breast carcinoma: We used the breast epithelial cell line MCF10A, poorly-metastatic breast cancer cell lines MCF7, T47D (ER-positive, PR-positive, and HER2-negative) and SKBR3 (ER-negative, PR-negative, and HER2-positive); highly metastatic breast cancer cell lines Hs578T, MDA-MB-231 (ER-negative, PR-negative, and HER2-negative), and MCF7-COX2 (ER-positive, PR-positive, and HER2-negative); as well as the highly metastatic stable miRNA-overexpression cell lines MCF7-miR526b, MCF7-miR655, and SKBR3-miR526b.